Key result
Aggressive rhythm control linked to ~24-point absolute LVEF gain in atrial arrhythmia with LVSD.
Why the study?
Determining whether tachycardia is an indicator or consequence of LVSD in patients with co-existing tachycardia and LVSD is difficult.
Does aggressive rhythm control therapy improve left ventricular systolic function in patients with persistent atrial arrhythmia and left ventricular systolic dysfunction, including those with severely enlarged left ventricular end-diastolic dimension (LVDd > 60 mm)?
Cohort (n=38)
Single-blind (echocardiographic data acquired by an investigator blinded to the study protocol)
No
Does aggressive rhythm control therapy improve left ventricular systolic function in patients with persistent atrial arrhythmia and left ventricular systolic dysfunction, including those with severely enlarged left ventricular end-diastolic dimension (LVDd > 60 mm)?
Answers are grounded in this paper and cite their sources.
Even in patients with severe left ventricular systolic dysfunction and enlarged left ventricular end-diastolic dimension (> 60 mm), systolic function is reversible after aggressive rhythm control for atrial arrhythmia, potentially avoiding unnecessary primary-prevention ICD implantation.
Introduction: Atrial arrhythmia (AA) and left ventricular systolic dysfunction (LVSD) frequently co-exist, and potentially represent growing public health problems. Determining whether tachycardia is an indicator or consequence of LVSD in patients with tachycardia and LVSD is difficult. Tachycardia-mediated cardiomyopathy (TCM) raises a “chicken or egg” question. Regardless of the etiology, patients with severe LVSD are considered candidates for the implantation of a cardioverter defibrillator as primary prevention. LVSD is well known to improve after successful treatment of AA in the TCM population, but enlarged left ventricular end-diastolic dimension (LVDd) is considered a parameter of irreversible LVSD. Hypothesis: Enlarged LVDd is not a predictor of irreversible LVSD in patients with AA. Methods: We assessed patients with persistent AA and heart failure (ejection fraction (EF) < 45%) who received aggressive rhythm control therapy and maintained sinus rhythm with catheter ablation, electrical cardioversion and anti-arrhythmic drugs. Echocardiographic parameters and concentrations of brain natriuretic peptide (BNP) were evaluated before and after treatment. Results: Participants comprised 38 consecutive patients with persistent AA and LVSD (36 men; mean age, 64.3 ± 8.8 years). Thirty-three patients (86.8%) could be restored to and maintained sinus rhythm. After rhythm control therapy, EF, left ventricular end-systolic volume (ESV) and BNP were improved in all patients (EF: 30.7 ± 10.9% to 54.6 ± 7.4%; ESV: 80.8 ± 32.4 ml to 51.7 ± 22.9 ml; BNP: 382.0 ± 251.1 pg/ml to 50.5 ± 30.7 pg/ml; P < 0.001 each). Conversely, no significant improvements were seen in LVDd or left ventricular end-diastolic volume (EDV) (LVDd: 54.8 ± 7.3 mm to 54.1 ± 5.0 mm, P = 0.40; EDV: 118.2 ± 37.7 ml to 109.2 ± 34.9 ml, P = 0.17). Enlarged LVDd > 60 mm was observed in 7 patients (21%) before treatment. EF was normalized in patients with severe LVSD (EF < 35%, 16/38, 48%). Conclusion: Unnecessary device implantation may be avoidable if aggressive rhythm control therapy is used in patients with AA and severe LVSD. Even in patients with severe LVSD and enlarged LVDd, LVSD is likely to prove reversible if AA is also present.
No takes yet. Share an insight, caveat, or question.
Matsuda et al. (2022) conducted a cohort in Persistent atrial arrhythmia and left ventricular systolic dysfunction (LVEF < 45%) (n=38). Aggressive rhythm control therapy (catheter ablation, electrical cardioversion, and Class I or III antiarrhythmic drugs) vs. Baseline during atrial arrhythmia (pre-treatment) or patients without enlarged LVDd (<= 60 mm) was evaluated on Change in left ventricular ejection fraction (LVEF) after restoration and maintenance of sinus rhythm (p=<0.001). Aggressive rhythm control therapy improved LVEF from 30.7% to 54.6% in patients with atrial arrhythmia and LVSD, including those with severely enlarged LVDd (> 60 mm).
Synapse has enriched 10 related papers. Consider them for comparative context: